Literature DB >> 360234

Baclofen in the treatment of schizophrenia: a pilot study.

J Schöpf, H Hucker.   

Abstract

10 chronic schizophrenics were treated with baclofen for 30 days in addition to the neuroleptic maintenance medication. The psychopathological findings were documented in intervals of 5 days using a global rating and the BPRS scale. 3 patients showed a definite slight improvement of their clinical condition, 2 patients showed a questionable improvement, whereas 5 patients did not change. The statistical analysis of the BPRS scale revealed a significant improvement of one higher order factor. Our pilot study suggests that baclofen may have positive effects on some schizophrenics.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 360234     DOI: 10.1055/s-0028-1094523

Source DB:  PubMed          Journal:  Pharmakopsychiatr Neuropsychopharmakol        ISSN: 0031-7098


  4 in total

1.  Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine.

Authors:  Marco Bortolato; Roberto Frau; Gian Nicola Aru; Marco Orrù; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

2.  Positive allosteric modulation of GABAB receptors ameliorates sensorimotor gating in rodent models.

Authors:  Roberto Frau; Valentina Bini; Giuliano Pillolla; Pari Malherbe; Alessandra Pardu; Andrew W Thomas; Paola Devoto; Marco Bortolato
Journal:  CNS Neurosci Ther       Date:  2014-04-07       Impact factor: 5.243

3.  GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.

Authors:  M J Gandal; J Sisti; K Klook; P I Ortinski; V Leitman; Y Liang; T Thieu; R Anderson; R C Pierce; G Jonak; R E Gur; G Carlson; S J Siegel
Journal:  Transl Psychiatry       Date:  2012-07-17       Impact factor: 6.222

Review 4.  Binding of clozapine to the GABAB receptor: clinical and structural insights.

Authors:  Pramod C Nair; Ross A McKinnon; John O Miners; Tarun Bastiampillai
Journal:  Mol Psychiatry       Date:  2020-03-13       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.